INTRODUCTION
Bactobilia is defined as the presence of microbial pathogens in bile and acute cholangitis is caused by bacterial infection in the setting of biliary obstruction. 1 The most com-mon predisposing factors of acute cholangitis are common bile duct stones, tumors of the pancreatobiliary system, and benign biliary stricture. 2, 3 In its most severe form, acute cholangitis may result in biliary sepsis or even multi-organ failure.
Consequently, morbidity rate and mortality rate of patients Fig. 1 . Study flow. Patients with acute cholangitis and biliary drainage were divided into groups according to time period and setting. Values are presented as mean±SD or n (%). CBD, common bile duct; IHD, intrahepatic bile duct; GB, gallbladder; AOV, ampulla of Vater. with acute cholangitis have increased. 4 Therefore, in addition to biliary drainage, empirical therapy with a broad-spectrum antimicrobial agent is warranted in management of acute cholangitis. However, recent studies have reported that isolates from acute cholangitis have changed due to increased use of biliary stents and prior exposure to antimicrobial agents. 5, 6 Rate of infection with extended-spectrum beta-lactamase (ESBL)-producing Gram-negative bacteria isolates has increased in both community-acquired infections and in hospital-acquired infections. 7, 8 Thus, knowledge of prevalence and antimicrobial susceptibility of the institution is essential to administration of the most effective empirical antimicrobial therapy.
In this study, we investigated the etiology of acute cholangitis and causative pathogens isolated from blood and bile culture of patients with acute cholangitis over a time period of six years. In addition, we also investigated changes of causative pathogens and their antimicrobial susceptibility over the time period and differences in causative pathogens and their antimicrobial susceptibility between community-acquired and hospital-acquired acute cholangitis.
SUBJECTS AND METHODS
Patients with acute cholangitis who received biliary drainage at a single university medical center between August 2006 and August 2012 were included in this study. Medical records of these patients were reviewed retrospectively.
Acute cholangitis was diagnosed when more than one of the following was found: 1) purulent bile in gross appearance, 2) 
RESULTS

Causes of acute cholangitis and biliary drainage
Causes of acute cholangitis and biliary drainage are described in Table 2 . The most common cause of acute cholangitis and biliary drainage was biliary stone (n=1,053, 66%), followed by cholangiocarcinoma (n=215, 13.5%), pancreatic head cancer (n=59, 3.7%), and ampulla of Vater tumor (n=59, 3.7%). No statistically significant difference in causes was observed between period 1 and period 2.
Changes of causative pathogens and their susceptibility over the time period
Data from comparison of baseline characteristics of the patients between two time periods are shown in Table 2 .
Although total bilirubin was higher in period 1 and frequency of bacteremia was higher in period 2, no statistically significant differences in other parameters were observed between the two time periods.
Changes of causative pathogens and their antimicrobial susceptibility over the time period of six years are described in 
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The Korean Journal of Gastroenterology Values are presented as mean±SD or n (%). CBD, common bile duct; IHD, intrahepatic bile duct; GB, gallbladder; AOV, ampulla of Vater. 8.0%, p=0.000) were less common in hospital-acquired cholangitis than in community-acquired cholangitis. Data from comparison of antimicrobial susceptibility between community-acquired cholangitis and hospital-acquired chol- angitis are shown in Table 5 . Amikacin and imipenem were the two antimicrobial agents showing the highest susceptibility in both groups. In hospital-acquired cholangitis, ampicillin, piperacillin-tazobactam, cephalosporins, and quinolones showed lower susceptibility than in community-acquired cholangitis.
Changes in antimicrobial susceptibility of ESBL-producing E. coli
Antimicrobial susceptibility of ESBL-producing E. coli was compared between period 1 and period 2 ( Table 6) , and its antimicrobial susceptibility was compared between community-acquired cholangitis and hospital-acquired cholangitis ( Table 7 ). Regardless of time period and setting, amikacin and imipenem showed the highest susceptibility.
Piperacillin-tazobactam showed decreased susceptibility in period 2 (85.8% vs. 76.6%, p=0.000), but similar susceptibility in community-acquired cholangitis and hospital-acquired cholangitis (77.2% vs. 71.0%, p=0.223).
DISCUSSION
Acute cholangitis is a medical emergency and can be life-threatening without appropriate treatment. In normal biliary tract, bile is sterile. However, bacterial colonization of bile occurs through ascension from the duodenum or translocation from the portal vein. 1, 9 Then, biliary obstruction re-sults in increased intraductal pressure and reflux of infected bile into blood and lymphatics. 1, 10 The most common cause of biliary obstruction and resultant acute cholangitis is common bile duct stone. 11 With an increase in number of interventions, such as surgery, percutaneous transhepatic biliary drainage, and ERCP, the rate of acute cholangitis in patients with malignant biliary obstruction has shown a gradual increase. 3, 12 Two studies from academic centers reported that bacteria were isolated from 31.2% and 80% of blood and from 71.7% and 96.3% of bile obtained from patients with acute cholangitis. 13, 14 Bacteria isolated from blood are similar to bacteria isolated from bile, therefore, isolation from bile culture can provide solid evidence for selection of a susceptible antimicrobial agent. 15, 16 In this study, bacteria were isolated from 14.1% of blood cultures, and from 95.2% of bile cultures. Bacteria were isolated from both blood and bile cultures in 7.6%. In other studies of acute cholangitis, the common causative pathogen isolated from blood and/or bile cultures was E. coli. 14, [17] [18] [19] [20] [21] [22] Similar to findings of previous studies, in this study, Gram-negative bacteria were predominantly found in 94% of patients with acute cholangitis. In addition, the most common Gram-negative pathogens were E. coli.
These results are similar to those from previous studies.
22-24
A study from Japan reported that Gram-negative aerobic bacteria was most frequently isolated from patients with biliary infection. 23 Bacteriologic studies of bile and blood cultures from Hong Kong showed that Gram-negative bacteria, particularly E. coli, were found most frequently. 17 A similar study from Poland reported that Gram-negative bacteria were isolated in 68.1% of bile cultures and the most predominant Gram-negative pathogen was E. coli. 24 In this study, the causative pathogen for more than one-third of cases was ESBL-producing E. coli isolated from blood or bile, and the causative pathogen for 6.3% of cases was ESBL-producing K. pneumoniae isolated from blood or bile. In addition, with regard to change of time period and antimicrobial susceptibility, ESBL-producing E. coli was the most common bacteria in both period 1 and period 2, but did not show a significant increase over time. Unlike previous studies 13, 14, 17, 21, 23 showing frequency of C. freundii to be less than 5%, frequency of C. freundii increased in this study. Previous studies have reported an increase in prevalence of resistant bacteria over time, change in their antimicrobial susceptibility, and difference according to region and country in which studies are conducted. 18, 20, [25] [26] [27] Tokyo Guidelines suggested that in cases of light acute cholangitis (grade I), use of a beta-lactam/beta-lactamase inhibitor such as piperacillin-tazobactam or ampicillin-sulbactam as monotherapy is adequate. 28 In cases of moderate (grade II) and severe (grade III) acute cholangitis, the recom- Typically, poor outcome is expected in infection by antibiotic-resistant bacteria. 30 According to the results of this study, Gram-negative bacteria showed high resistance to ampicillin, ciprofloxacin, and second, third, and fourth generation cephalosporins in the past and at present. However, cefotetan showed increased susceptibility over the time period.
Piperacillin/tazobactam showed susceptibility of 65.6% in period 1; however, it increased to 68.1% in period 2 (p=0.455). The rate of resistance to the cephalosporins disqualifies them as first-line empiric antimicrobial agents against acute cholangitis. However, cephalosporins are still used as first line empiric antimicrobial agents. Susceptibility of amikacin did not show a significant change, with 80.9% in period 1, and 90% in period 2, respectively (p=0.000).
Ampicillin and gentamicin were the two empiric antimicrobial agents of choice in the past. With increasing resistance to ampicillin and significant nephrotoxicity caused by aminoglycosides, this combination is not preferred. 31, 32 Although aminoglycosides show low concentration in bile, they appear to possess high in vitro efficiency against bile pathogens. The issue regarding drug penetration remains controversial. Only a few ex vivo studies 32 and clinical in vivo observations with inconsistent results have been reported on this topic. 33, 34 Aminoglycosides, alone or as part of a combination regimen, were considered effective against acute cholangitis. [35] [36] [37] Despite high in vitro efficiency against causative pathogen, use of amikacin in treatment of acute cholangitis is controversial due to low concentration in bile. Ciprofloxacin is the only antibiotic actively secreted into bile, especially in cases of cholestasis. 17, 38 When bacterial infection spreads beyond bile duct and becomes systemic, it is of critical importance that the antibiotic be effective as soon as possible in order to control bacteremia. Serum concentrations of the studied antibiotics are sufficient to eradicate the infection. 24 However, except for ciprofloxacin, most of the drugs are not actively secreted into the bile, and their bile concentrations are lower than those in blood. However, unlike the other studies, in this study, nearly one half of Gram-negative bacteria showed resistance to ciprofloxacin. Therefore, ciprofloxacin is not an effective empiric antimicrobial agent for acute cholangitis in our institution. In other study, cefepime was very effective despite limited penetration into the bile during cholestasis. 39, 40 However, in this study, it was not effective in both period 1 and period 2 (64.3% vs. 62.3%, p=0.578). In this study, cefotetan showed increased susceptibility over time (55.6% vs. 74.8%, p=0.000). However, high in vivo susceptibility of cefotetan does not translate into high in vitro susceptibility. Therefore, cefotetan cannot be used in treatment of ESBL-producing E. coli. 41, 42 Hospital-acquired infection has been introduced as a risk factor of antibiotic-resistant organism acquisition in previous studies. 27, 29 Breach of the enteric-biliary barrier due to stent placement may be an important factor in mixed bacterial colonization of the bile duct. 5 Patients with long hospital stays may have increased chances of exposure to additional antimicrobial agents and to other patients with resistant organisms. As expected, in this study, ESBL-producing E. coli and C. freundii were more frequently isolated in hospital-acquired cholangitis. According to a study of biliary tract infections conducted in a tertiary referral center, prevalence of ESBL-producing E. coli and Klebsiella species showed a dramatic increase, from 2.3% to 43.9%, over a 10-year period. 43 Successful endoscopic biliary drainage with 2-7 days of antimicrobial therapy until resolution of fever appeared to be safe and effective in a prospective, single-arm, exploratory study of 18 patients with acute cholangitis. 44 However, it is premature to conclude that urgent, adequate biliary drainage with a short course of antimicrobial therapy would decrease antimicrobial resistance without results from a prospective multicenter trial involving a large number of patients. Currently, acute cholangitis is best managed by prompt administration of antimicrobial agent and early and adequate biliary drainage.
This study has some limitations. First, the study was conducted at a single university medical center. Species and prevalence of causative pathogens differ from one institution to another. Therefore, the findings of this study may not be generalized. Conduct of a multicenter study will be necessary in order to overcome this limitation. Second, clinical outcome of patients with acute cholangitis was not assessed. Since administration of the antimicrobial agent according to results of in vitro assay of susceptibility does not always guarantee successful clinical outcome, assessment of actual clinical outcome is needed.
In conclusion, the most common causative pathogen of acute cholangitis at our institution was ESBL-producing E. coli. Prevalence of C. freundii showed a significant increase over a time period of six years. Imipenem is still the most effective antimicrobial agent regardless of time period and setting. However, in order to reduce emergence of pathogens with resistance to carbapenems, they should be used only as an alternative when initial empiric antimicrobial agents such as beta-lactam/beta-lactamase inhibitors or third-or fourth-generation cephalosporins with or without metronidazole fail or microbiologic isolates reveal resistant pathogens. Conduct of further prospective, multicenter studies will be needed in order to make generalizations and to assess clinical significance of changes in causative pathogens and their antimicrobial susceptibility.
